Supporting opioid use disorder (OUD) patients on their road to recovery

Labcorp’s MAT urine drug testing helps to optimize appropriate care, including:Testing options that can be individualized based on the patient’s past use history, time in recovery and perceived risk of relapsePanels are designed to confirm compliance to OUD therapy and detect use of common illicit or prescribed controlled substances, including buprenorphine, norbuprenorphine and naloxoneResults that address some of the variability inherent to urine drug testing (e.g., donor’s hydration status) and are normalized to the creatinine concentration in that urine sampleThe norbuprenorphine/buprenorphine (N/B) ratio, an additional interpretive dimension to MAT drug testing results

Comprehensive genomic and immune profiling for the detection of clinically significant tumor biomarkers

Analytical validation of OmniSeq® INSIGHT whole transcriptome sequencing assay to facilitate precision oncology through tumoronly testing in solid tumors

Analytical validation of OmniSeq® INSIGHT whole exome sequencing assay to facilitate precision oncology through tumor only testing in solid tumors

Validation of automated nucleic acid extraction using Covaris® Gen3 extraction methodology on the Assay-Ready Workstation

Enabling Access to Genomic Profiling through Decentralized Liquid Biopsy Solution PGDx elioTM plasma focus Dx

Labcorp Acquires Select Assets of Lab Works

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has finalized its acquisition of select assets and molecular testing location of Lab Works, an accredited independent clinical laboratory located in Birmingham, Alabama. 

Molecular Tumor Board: 58-year-old male with breast carcinoma and BRCA2 R3128* mutation

Though less common than in women, understanding male breast cancer and symptoms can lead to earlier detection and improved outcomes.

Labcorp Perspectives: Optimizing biomarker testing in advanced NSCLC: Insights on comprehensive genomic profiling (CGP)

In the latest episode of Labcorp Perspectives: Oncology, Dr. Rebecca Ann Previs and Dr. Kyle Strickland, directors of medical affairs at Labcorp Oncology, delve into the significant advantages of comprehensive genomic profiling (CGP) over single-gene testing in patients with advanced non-small cell lung cancer (NSCLC). This study, using OmniSeq® INSIGHT, showed that CGP enables that patients with NSCLC to be tested for all recommended biomarkers at once, providing the best chance of identifying effective treatment options.

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C. , Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn